ORGO - Organogenesis: Undervalued And Promising Investment Opportunity For 2020
Today, we will study why Organogenesis (ORGO) is a high growth yet undervalued opportunity in 2020.
Company overview
Organogenesis is a regenerative medicine company focusing on the development and commercialization of products for treating chronic and acute wounds and healing of musculoskeletal injuries. Headquartered in Canton, Massachusetts, the company was founded in 1985.
The company’s major advanced wound care products include Apligraf, Dermagraft, Affinity, and NuShield. The company’s key surgical and sports medicine products include ReNu, NuCel, NuShield, Affinity, and PuraPly AM. The company is targeting attractive end-markets such as advanced wound care